<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03406962</url>
  </required_header>
  <id_info>
    <org_study_id>IMD-001</org_study_id>
    <nct_id>NCT03406962</nct_id>
  </id_info>
  <brief_title>MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)</brief_title>
  <official_title>A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell Transplantation (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Magenta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Magenta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety and efficacy of using MGTA-456 in patients with
      Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 2 study is designed to evaluate the safety and efficacy of MGTA-456 after
      myeloablative conditioning to induce rapid and sustained hematopoietic engraftment with
      replacement of the specific protein product missing or defective in the patient with an IMD.
      The study aims to enhance the efficacy of umbilical cord blood transplantation (UCBT), to
      preserve neurodevelopment in patients with selected IMDs. Since MGTA-456 offers increased
      numbers of HSCs over standard UCB, it is expected to reduce the risks of prolonged
      neutropenia and thrombocytopenia and graft failure, and potentially transplant-related
      mortality (TRM). Patients with Hurler syndrome (also referred to as mucopolysaccharidosis-1H
      (MPS-1H)), cerebral adrenoleukodystrophy (cALD), metachromatic leukodystrophy (MLD) or
      globoid cell leukodystrophy (GLD) (also referred to as Krabbe disease) could be eligible for
      this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of engraftment</measure>
    <time_frame>42 days</time_frame>
    <description>Engraftment is defined as achieving an absolute neutrophil count (ANC) ≥0.5 × 10⁹/L for 3 consecutive days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of infusion toxicities</measure>
    <time_frame>48 hours</time_frame>
    <description>Incidence of MGTA-456-related adverse events (AEs) that limit MGTA-456 administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Inherited Metabolic Disorders (IMD)</condition>
  <arm_group>
    <arm_group_label>MGTA-456</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGTA-456 is an expanded umbilical cord blood product used during single umbilical cord blood transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGTA-456</intervention_name>
    <description>Hematopoietic stem cell transplantation will be done with the cell therapy product MGTA-456.</description>
    <arm_group_label>MGTA-456</arm_group_label>
    <other_name>HSC835</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with Hurler syndrome, metachromatic leukodystrophy (MLD), globoid cell
             leukodystrophy (GLD or Krabbe) or cerebral adrenoleukodystrophy (cALD)

          -  Adequate organ function

          -  Availability of eligible donor material

        Exclusion Criteria:

          -  Availability of a matched-related donor who is not a carrier of the same genetic
             defect

          -  Active infection at screening

          -  Prior myeloablative conditioning

          -  History of human immunodeficiency virus (HIV) infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magenta Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Magenta Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magenta Clinical Trials</last_name>
    <phone>857-242-0170</phone>
    <email>clinicaltrials@magentatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul J Orchard, MD</last_name>
      <phone>612-626-2313</phone>
      <email>orcha001@umn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inherited metabolic disorders</keyword>
  <keyword>cerebral adrenoleukodystrophy</keyword>
  <keyword>Hurler syndrome</keyword>
  <keyword>globoid cell leukodystrophy</keyword>
  <keyword>Krabbe disease</keyword>
  <keyword>metachromatic leukodystrophy</keyword>
  <keyword>hematopoietic stem cells</keyword>
  <keyword>hematopoietic stem cell transplant</keyword>
  <keyword>umbilical cord blood</keyword>
  <keyword>umbilical cord blood transplant</keyword>
  <keyword>MGTA-456</keyword>
  <keyword>myeloablative conditioning regimen</keyword>
  <keyword>bone marrow transplant</keyword>
  <keyword>mucopolysaccharidosis-1H</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

